Heterogeneity in downstream atrophy in Alzheimer’s disease (AD) is predominantly investigated in relation to pathological hallmarks (Aβ, tau) and co-pathologies (cerebrovascular burden) independently. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.